lcp
We have detected you are using Internet Explorer. To provide the best and most secure experience, please use a modern browser as we do not support Internet Explorer.

Optimizing HFpEF Management with SGLT2 Inhibitors - Mini Audit

The Activity

The activity includes:

  • A short recorded presentation on the latest evidence for the management of Chronic Heart Failure with preserved ejection fraction (from Hot Topics GP Update 2023).
  • A review of the latest evidence published on the management of patients with HFpEF.
  • A review of three patient records and comparison to the best practice guidelines.
  • A reflection on the management and possible changes to practice.

Background

HFpEF is defined as symptoms and signs of heart failure with an EF >50% and echocardiographic features of left atrial enlargement, pulmonary hypertension and impaired diastolic filling.1 It is most commonly caused by hypertensive heart disease.

Pharmacological management includes diuretics for symptom control and antihypertensives to optimise BP control.2 But until recently, no pharmacological interventions have been shown to improve outcomes in patients with HFpEF. However, two recent studies show convincing evidence that SGLT2 inhibitors improve prognosis in patients with HFpEF, irrespective of diabetes status.3,4

A 2023 review of HFpEF states that ‘first-line pharmacologic therapy consists of SGLT2 inhibitors, such as dapagliflozin or empagliflozin, which reduced heart failure related hospitalisation or  cardiovascular death by approximately 20% compared with placebo in randomised clinical trials.’5

Audience

This activity is designed for GPs and GP registrars.

SHARE:

This course has been formally accredited with RACGP and ACRRM. 

RACGP Activity Number: 495679

ACRRM Activity Number: 30004

Medcast

Mini-audit

Available anytime
Learning

Educational Activities: 1 hours

Measuring Outcomes: 2 hours

Areas Of Interest: Cardiovascular, Chronic diseases

Audience

Medical Practitioners

Free

Or follow us on social media

SUBSCRIBE & SAVE

Become a member and get unlimited access to this course and others with Medcast PLUS.

From $35/month

  • All your CPD
  • 100+ hours of premium courses
  • Exclusive content
LEARN MORE
Related Courses
Loading...
BECOME A MEMBER & SAVE

Access Optimizing HFpEF Management with SGLT2 Inhibitors - Mini Audit and many others with Medcast Plus